Neurofibromatosis type 1 study in Egypt
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study looks at how neurofibromatosis type 1 (NF1) affects people in Egypt, including how it progresses and how it is managed. Researchers will review medical records of patients diagnosed with NF1 between 2010 and 2023 to learn more about the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male or female of any age.
- You must have been diagnosed with neurofibromatosis type 1 (NF1) between January 1, 2010 and December 31, 2023.
- Your NF1 diagnosis must meet the official diagnostic criteria (NIH guidelines or updated criteria).
- Your medical records must clearly show the NF1 diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This study is looking for adults with NF1 who have had a plexiform neurofibroma. It aims to find better ways to detect tumors early, which could help with treatment decisions.
This study looks for better ways to measure how much tumor activity people with neurofibromatosis type 1 (NF1) have over time. The goal is to develop “biomarkers,” which are test results that may help doctors track disease more easily.
This study uses special MRI scans plus computer (AI) analysis to look for early, possibly cancer-related skin or tissue changes in children with neurofibromatosis type 1 (NF1). If it works, it could help doctors detect concerning changes earlier and plan care sooner.
This study looks at how young children with NF1 walk. It aims to learn more about their movement patterns to help improve care.
This study is collecting information about adults in Russia with Neurofibromatosis type 1 who have symptomatic plexiform neurofibromas and have not yet been treated with a MEK inhibitor. It aims to better understand the condition and its treatment in real-world settings.
Hear when a new Neurofibromatosis Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.